Is developing and legitimizing pharmaceutical-like, reduced-harm tobacco products giving the tobacco industry a new lease on life? Tobacco control researchers, Yogi Hale Hendlin, PhD, Jesse Elias, MA and Pamela Ling, MD, MPH pose this question in their study published in Annals of Internal Medicine, July 2017. They call this phenomenon the pharmaceuticalization of the tobacco industry and conclude that the industry is attempting to remake its image as being responsive to health concerns, although, this rebranding tactic actually brings a new threat to public health. Read the full article.
